| 1 |
31916635 | Synthesis of novel flexible tamoxifen analogues to overcome CYP2D6 polymorphism and their biological evaluation on MCF-7 cell line. | 2020 Jun |
1 |
| 2 |
31398422 | Corrigendum to "Plasma endoxifen and 4-hydroxytamoxifen levels in CYP2D6(C100T) carrying breast cancer patients and association with serum cholesterol" [Toxicology and Applied Pharmacology, 378 (2019) 114619]. | 2019 Oct 1 |
1 |
| 3 |
29385237 | Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. | 2018 May |
1 |
| 4 |
29436156 | Cytochrome P450 Genetic Variation Associated with Tamoxifen Biotransformation in American Indian and Alaska Native People. | 2018 May |
1 |
| 5 |
29245979 | Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer. | 2017 Nov 21 |
1 |
| 6 |
26446141 | Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch. | 2016 Feb |
1 |
| 7 |
26896706 | Design and synthesis of novel tamoxifen analogues that avoid CYP2D6 metabolism. | 2016 Apr 13 |
1 |
| 8 |
26898104 | Design and synthesis of novel flexible ester-containing analogs of tamoxifen and their evaluation as anticancer agents. | 2016 |
1 |
| 9 |
27198207 | Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1. | 2016 Dec |
2 |
| 10 |
26071758 | Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer. | 2015 Jul |
1 |
| 11 |
24434530 | Successful use of agomelatine in the treatment of major depression in a woman taking tamoxifen: a case report. | 2014 Jan-Feb |
2 |
| 12 |
24881593 | Mitochondria: the gateway for tamoxifen-induced liver injury. | 2014 Sep 2 |
1 |
| 13 |
25073551 | Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes. | 2014 Dec |
2 |
| 14 |
25258390 | Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients. | 2014 Oct |
1 |
| 15 |
23781139 | Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancer. | 2013 |
1 |
| 16 |
21947681 | Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients. | 2012 Jan |
5 |
| 17 |
21451508 | Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. | 2011 May |
1 |
| 18 |
21906462 | The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review. | 2011 Sep |
1 |
| 19 |
20124171 | Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. | 2010 Mar 10 |
1 |
| 20 |
21086978 | Tamoxifen metabolite isomer separation and quantification by liquid chromatography-tandem mass spectrometry. | 2010 Dec 15 |
2 |
| 21 |
18294285 | Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. | 2008 May |
3 |
| 22 |
18637494 | Pharmacogenomics of endocrine therapy in breast cancer. | 2008 |
2 |
| 23 |
12623757 | CYP2D6-mediated catalysis of tamoxifen aromatic hydroxylation with an NIH shift: similar hydroxylation mechanism in chicken, rat and human liver microsomes. | 2003 Feb |
1 |
| 24 |
12769667 | Tamoxifen: is it safe? Comparison of activation and detoxication mechanisms in rodents and in humans. | 2003 Jun |
1 |